There’s a conversation happening quietly in bariatric communities that deserves to be spoken about more openly. A growing number of people who’ve had gastric sleeve surgery are also using GLP-1 receptor agonist medications – semaglutide (Ozempic, Wegovy), liraglutide, tirzepatide. And a significant number of them feel like they need to keep it quiet, because using medication after surgery somehow means they’ve failed.
It doesn’t. And the logic that says it does doesn’t hold up.
What GLP-1 medications do
GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone naturally produced in the gut after eating. They slow gastric emptying, reduce appetite, and influence how the brain responds to food and satiety signals – all of which supports weight management and blood sugar regulation.
Here’s what makes the post-sleeve context particularly interesting: gastric sleeve surgery also increases GLP-1 production naturally. Part of the reason the sleeve works as well as it does is because the anatomical changes cause elevated GLP-1 – reducing hunger and improving satiety. The medication and the surgery are, in a meaningful sense, working on the same biological pathway. Using a GLP-1 medication after a sleeve isn’t contradicting the surgery – it’s reinforcing the same mechanism.
Why people use them after surgery
Weight loss after gastric sleeve isn’t linear and the hormonal effects don’t stay constant. As months and years pass, hunger hormones can partially recalibrate, the stomach adapts slightly, and the rate of loss slows or plateaus. For some people, particularly those with significant regain or a plateau they can’t shift through dietary measures, a GLP-1 medication helps pick up where the restriction alone is no longer sufficient.
For others it addresses ongoing hunger that surgery didn’t fully resolve – a legitimate physiological reality for some patients, not a failure of willpower. For people with type 2 diabetes or pre-diabetic markers, GLP-1s may be prescribed as much for blood sugar management as for weight.
The stigma doesn’t make sense
There’s a strange logic that sometimes circulates in bariatric communities – the idea that surgery is an acceptable medical intervention, but medication somehow represents a lesser or more shameful choice. That taking Ozempic after a sleeve means you didn’t try hard enough, or that you’re cheating.
Nobody applies this logic to other chronic conditions. Nobody says that taking antihypertensives after lifestyle changes means you failed to manage your blood pressure, or that using insulin alongside diet changes is somehow not a legitimate approach to diabetes. Long-term conditions are managed with long-term tools. Obesity is a chronic condition with complex biological drivers – it frequently requires more than a single intervention, at a single point in time, to manage across a lifetime.
The sleeve was never described as a cure. It was described as a tool. Using additional tools to sustain what the sleeve started is entirely coherent with that framing.
Practical considerations
GLP-1 medications are prescription-only in the UK. Ozempic is licensed for type 2 diabetes; Wegovy is licensed for weight management in people meeting specific criteria. Access via NHS is currently limited and criteria-based – your GP is the starting point for a conversation about eligibility.
Private prescribing is available but comes with cost considerations and requires proper medical oversight. Self-administering semaglutide obtained from unregulated sources – which does happen – carries real risks and is something we’d actively discourage.
If you’re post-sleeve and considering whether a GLP-1 medication might be appropriate for you, the right move is an open conversation with your GP or bariatric team. They can assess whether it’s indicated, whether there are contraindications, and how it would fit alongside your current regimen.
You haven’t failed
Using every tool available to you to maintain your health is not failure. It’s the opposite. You had surgery to improve your life. If additional medical support helps you sustain that improvement – use it, discuss it openly, and don’t apologise for it.
Sources cited in this post: NICE TA664 – Semaglutide for managing overweight and obesity (National Institute for Health and Care Excellence)
NHS – Weight loss medicines: GLP-1 receptor agonists
BOMSS – Position statement on the use of GLP-1 receptor agonists in bariatric patients
NICE CG189 – Obesity: identification, assessment and management
- NHS, “Weight loss surgery”: https://www.nhs.uk/conditions/weight-loss-surgery/
- British Obesity & Metabolic Surgery Society (BOMSS): https://bomss.org/
- NHS, “Wegovy (semaglutide)”: https://www.nhs.uk/medicines/semaglutide-for-weight-loss/
About this content
This blog is written by James and Kirsten, a couple from the UK who had gastric sleeve surgery together in March 2024.
We started this blog because we couldn't find any sources of content that details before surgery, the surgery and then life post surgery - so we decided to write one ourselves.
Everything on this site is based on our own experience and the research we have done along the way. It is not medical advice. Gastric sleeve surgery is a serious procedure and every patient's journey is different. Please always consult your own bariatric team or GP before making any decisions about your health or treatment.
Some posts on this site may contain featured or sponsored content, or affiliate links. Where this is the case, it will always be clearly stated at the top of the article. Our opinions are always our own.
Publish Date: 10 December 2025 | Last Reviewed: 27 June 2026 | Next Planned Review: 27 December 2027